Motavizumab
Phase 3Monoclonal antibody
AstraZenecaMotavizumab is one of 58 biologic programs targeting Wheezing. It is currently in Phase 3.
2
Indications
9
Total Trials
0
Active Trials
57
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
56 competitors in Congenital Heart Disease
#DrugCompanyPhaseTrials
1Tracleer
Johnson & JohnsonApproved
Opsumit
Johnson & JohnsonApproved
Theo-Dur
PfizerApproved
Intropin
PfizerApproved
Remodulin
United TherapeuticsApproved
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Jardiance
Boehringer IngelheimApproved
Pepcid
KKenvue Brands
Approved
Feraheme
AAzurity Pharmaceuticals
Approved
Decadron
AAspen Global Incorporated
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Respiratory Syncytial Virus (RSV)5 trials
Prevention1 trial
Wheezing1 trial
Congenital Heart Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Motavizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company